A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.

Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA

Diabetes, obesity & metabolism29 Nov 2016Cited by 116 (Europe PMC)

PMID27717195DOI10.1111/dom.12804PepBankPUB-27717195

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with type 2 diabetes on oral glucose-lowering medication, GLP-1 receptor agonists reduced HbA1c more than insulin.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group lowered HbA1c slightly more than insulin did.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Comparator
Insulin
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Compared to insulin, GLP-1 RAs reduced HbA1c more effectively (Δ -.12%, P < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Prospective, randomized trials comparing GLP-1 RA and insulin treatment head-to-head as add-on to OGLM were identified (PubMed).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2771719501
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with type 2 diabetes, basal insulin reduced fasting plasma glucose more than GLP-1 receptor agonists did.
In plain wordsIn adults with type 2 diabetes, basal insulin lowered fasting blood sugar more than GLP-1 drugs as a group.
Peptide
Liraglutide
Outcome
IncreaseFasting plasma glucose
Study
n: not reported in source
Comparator
Insulin
Outcome group
Glycemic control · Metabolic and weight
Measurements
Fasting plasma glucose difference
−1.8 mmol/L
basal insulin vs GLP-1 RAs
Source sentences
Summary
Basal insulin was more effective in reducing fasting plasma glucose (Δ -1.8 mmol/L, P < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Prospective, randomized trials comparing GLP-1 RA and insulin treatment head-to-head as add-on to OGLM were identified (PubMed).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2771719502
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with type 2 diabetes, GLP-1 receptor agonists reduced body weight more than insulin.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group led to more weight loss than insulin.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Insulin
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight difference
−3.71 kg
GLP-1 RAs vs insulin
Source sentences
Summary
GLP-1 RAs reduced bodyweight more effectively (Δ -3.71 kg; P < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Prospective, randomized trials comparing GLP-1 RA and insulin treatment head-to-head as add-on to OGLM were identified (PubMed).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2771719503
04HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In patients with type 2 diabetes, the proportion with hypoglycaemic episodes was 34% lower with GLP-1 receptor agonists than with insulin.
In plain wordsIn adults with type 2 diabetes, fewer people had low blood sugar episodes with GLP-1 drugs than with insulin.
Peptide
Liraglutide
Outcome
DecreasePatients with hypoglycaemic episodes
Study
n: not reported in source
Comparator
Insulin
Outcome group
Adverse events · Metabolic and weight
Measurements
Lower proportion with hypoglycaemia
34%
GLP-1 RAs vs insulin
Source sentences
Summary
The proportion of patients experiencing hypoglycaemic episodes was 34% lower with GLP-1 RAs ( P < .0001)
1 context sentence(design, population, supporting numbers)
Summary · context
Prospective, randomized trials comparing GLP-1 RA and insulin treatment head-to-head as add-on to OGLM were identified (PubMed).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2771719504
05HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In patients with type 2 diabetes, severe hypoglycaemia showed a similar trend toward lower frequency with GLP-1 receptor agonists than with insulin.
In plain wordsIn adults with type 2 diabetes, severe low blood sugar showed a similar trend toward being less common with GLP-1 drugs than with insulin.
Peptide
Liraglutide
Outcome
DecreaseSevere hypoglycaemia
Study
n: not reported in source
Comparator
Insulin
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
with a similar trend for severe hypoglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Prospective, randomized trials comparing GLP-1 RA and insulin treatment head-to-head as add-on to OGLM were identified (PubMed).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2771719505
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with type 2 diabetes, systolic blood pressure was lower with GLP-1 receptor agonists than with insulin.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group were linked to lower systolic blood pressure than insulin.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Insulin
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
Systolic blood pressure was lower and heartrate was higher with GLP-1 RAs ( P < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Prospective, randomized trials comparing GLP-1 RA and insulin treatment head-to-head as add-on to OGLM were identified (PubMed).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2771719506
07HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In patients with type 2 diabetes, heart rate was higher with GLP-1 receptor agonists than with insulin.
In plain wordsIn adults with type 2 diabetes, heart rate was higher with GLP-1 drugs as a group than with insulin.
Peptide
Liraglutide
Outcome
IncreaseHeart rate
Study
n: not reported in source
Comparator
Insulin
Outcome group
Adverse events · Cardiovascular
Source sentences
Summary
Systolic blood pressure was lower and heartrate was higher with GLP-1 RAs ( P < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Prospective, randomized trials comparing GLP-1 RA and insulin treatment head-to-head as add-on to OGLM were identified (PubMed).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2771719507
08HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with type 2 diabetes, triglycerides were significantly lower with GLP-1 receptor agonists than with insulin.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group were linked to lower triglycerides than insulin.
Peptide
Liraglutide
Outcome
DecreaseTriglycerides
Study
n: not reported in source
Comparator
Insulin
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
Triglycerides and LDL cholesterol were significantly lower with GLP-1 RAs.
1 context sentence(design, population, supporting numbers)
Summary · context
Prospective, randomized trials comparing GLP-1 RA and insulin treatment head-to-head as add-on to OGLM were identified (PubMed).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2771719508
09HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with type 2 diabetes, LDL cholesterol was significantly lower with GLP-1 receptor agonists than with insulin.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group were linked to lower LDL cholesterol than insulin.
Peptide
Liraglutide
Outcome
DecreaseLDL cholesterol
Study
n: not reported in source
Comparator
Insulin
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
Triglycerides and LDL cholesterol were significantly lower with GLP-1 RAs.
1 context sentence(design, population, supporting numbers)
Summary · context
Prospective, randomized trials comparing GLP-1 RA and insulin treatment head-to-head as add-on to OGLM were identified (PubMed).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2771719509

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase not statedNCT03959865

GLP-1 REceptor Agonists and Real World EvIdeNce

University of Padovan = 6,00019 Dec 2018 to est. 31 May 2019

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 22 May 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.